TransCode Therapeutics Inc. RNAZ

TransCode Therapeutics reported advancements to its global IP portfolio in RNA-based immuno-oncology. IP Australia accepted an application (No. 2019349817) for 'Compositions and Methods for Immune Checkpoint Inhibition,' covering nanoparticle systems delivering siRNA to cancer, with an iron oxide core, dextran coating, and covalently linked siRNA; claims span treatments across colon, lung, breast, pancreatic, and ovarian cancers. In Japan, the JPO issued a Notice of Allowance and granted Japanese Patent No. 7886877 for 'Template Directed Immunomodulation for Cancer Therapy,' protecting RNA-based immunomodulatory compositions, including 5′ triphosphate-modified RNA designed to activate innate pathways such as RIG-I in tumors and tumor microenvironment; claims cover miR-21-expressing cancers and nanoparticle delivery with magnetic or polymer-coated targeting. Australian rights are expected to grant with expiry around Sept 6, 2039. The portfolio supports delivery platform and immuno-oncology capabilities and aligns with the lead candidate TTX-MC138. Strengthened IP in key markets broadens defensible platform and may uplift long-term value and strategic options.

TransCode Therapeutics published results showing TTX-MC138 extends survival in a preclinical breast cancer bone metastasis model. Positive preclinical survival data on lead candidate TTX-MC138 supports further development but remains early-stage.

TransCode Therapeutics Inc. introduces RNA therapeutics to advance its treatment pipeline and research efforts. RNA therapeutics introduction signals major strategic progress with potential to alter company trajectory.

TransCode Therapeutics completes Phase 1a trial for TTX-MC138, reporting safety and disease stabilization data in metastatic cancer patients. Successful Phase 1a completion for lead candidate TTX-MC138 advances pipeline and supports further development steps.

TransCode Therapeutics RNA therapeutic achieved 64% stable disease rate in colorectal cancer Phase 1 study. Positive Phase 1 data for TransCode lead asset supports clinical advancement and raises investor interest.

TransCode Therapeutics (RNAZ) appoints Dr. Anna Moore as Chair of its Scientific Advisory Board and announces a Sponsored Research Agreement with Michigan State University. Appointing an imaging expert as SAB Chair and securing a university research agreement moderately advances R&D capabilities and investor sentiment.

TransCode Therapeutics enters agreements for up to $20 million in flexible financing, extending its cash runway into late 2027 or early 2028. Up to $20 million flexible financing significantly extends cash runway into late 2027/early 2028, bolstering operational stability and investor confidence.

TransCode Therapeutics Inc. (RNAZ) secures exclusive, worldwide, fully paid-up, royalty-free license to develop and commercialize a next-generation oncolytic immunotherapy platform via all-stock transaction. Exclusive royalty-free license to next-gen oncolytic immunotherapy platform via all-stock deal significantly bolsters TransCode's oncology pipeline and competitive positioning.

TransCode Therapeutics announced publication of preclinical testing results for its RIG-I immunotherapeutic candidate, demonstrating efficacy in preclinical models and supporting advancement toward clinical development. Positive preclinical data publication validates RIG-I candidate and bolsters oncology pipeline progress without reaching clinical-stage milestones.

TransCode Therapeutics Inc. and Quantum Leap have submitted an IND amendment for a Phase 2a clinical trial involving TTX-MC138. This amendment aims to enhance the trial's design and objectives, focusing on the treatment of cancer. The collaboration is expected to advance the development of TTX-MC138, which targets specific cancer types and aims to improve patient outcomes. The IND amendment for a Phase 2a trial represents a significant step in the development of TTX-MC138, potentially impacting the company's future trajectory and market performance.

TransCode Therapeutics Inc. announced the publication of preclinical data that supports the therapeutic potential of TTX-MC138 in treating glioblastoma. The findings indicate that TTX-MC138 may effectively target and inhibit tumor growth in this aggressive form of brain cancer, highlighting its promise as a novel treatment option. The publication of preclinical data suggests significant advancements in treatment options for glioblastoma, potentially impacting the company's future performance and market position.

TransCode Therapeutics Inc. has appointed Jack E. Stover to its Board of Directors, expanding its leadership team. Stover brings extensive experience in the biotechnology sector, having held various executive roles and served on multiple boards. His expertise is expected to enhance the company's strategic direction and operational effectiveness as it advances its RNA-based therapeutics. The appointment of a seasoned executive is likely to positively influence the company's strategic direction and operational capabilities.

TransCode Therapeutics Inc. and Quantum Leap Healthcare Collaborative have initiated a Phase 2a dose-expansion trial for TTX-MC138, following positive results from TransCode's Phase 1 trial. This advancement aims to further evaluate the efficacy and safety of TTX-MC138 in treating cancer, building on the encouraging data obtained previously. The initiation of a Phase 2a trial represents a significant step in product development that could enhance the company's market position and investor sentiment.

TransCode Therapeutics Inc. has appointed Dr. Michel Janicot as Senior Development Officer, expanding its executive team. Dr. Janicot brings extensive experience in drug development and regulatory strategy, which is expected to enhance the company's capabilities in advancing its RNA-based therapeutics. The appointment of a seasoned executive may positively influence product development and operational efficiency.

TransCode Therapeutics Inc. presented preliminary data from its completed Phase 1a study of TTX-MC138 in metastatic disease at the European Society for Medical Oncology (ESMO) conference. The study aimed to evaluate the safety and efficacy of TTX-MC138, a therapeutic candidate targeting metastatic cancer. Initial results indicate potential benefits, contributing to the company's ongoing research efforts in oncology. Preliminary data from the Phase 1a study suggests significant potential for TTX-MC138, which could influence future product development and market positioning.

TransCode Therapeutics Inc. announced its acquisition of Polynoma, a company focused on developing treatments for melanoma. The deal includes a strategic investment from CK Life Sciences, which is expected to enhance TransCode's capabilities in RNA-based therapeutics. This acquisition aligns with TransCode's mission to advance its pipeline and expand its market presence in oncology. The acquisition of Polynoma and investment from CK Life Sciences are significant strategic moves that could enhance TransCode's product offerings and market position in the oncology sector.

TransCode Therapeutics Inc. (RNAZ) has acquired Polynoma and secured $25 million in strategic financing from a subsidiary of CK Life Sciences. This move aims to establish a unique immuno-oncology and metastatic prevention oncology company, positioning RNAZ for advancements in cancer treatment. The acquisition and financing are significant strategic moves that could enhance RNAZ's competitive position in the oncology market.

TransCode Therapeutics, Inc. (Nasdaq: RNAZ) has appointed Dr. Phillip D. Zamore, a pioneer in RNA interference and co-founder of Alnylam Pharmaceuticals, to its Scientific Advisory Board. Dr. Zamore, currently the Gretchen Stone Cook Professor of Biomedical Sciences at the University of Massachusetts Chan Medical School, will leverage his expertise in RNA biology to advance TransCode's RNA-targeted cancer therapies. The company focuses on treating metastatic disease using its proprietary TTX nanoparticle platform, with its lead candidate targeting tumors that overexpress microRNA-10b. The appointment of a prominent figure like Dr. Zamore is likely to significantly enhance TransCode's research capabilities and strategic direction in RNA oncology.

TransCode Therapeutics Inc. has successfully completed the initial dosing of patients in Cohort 4 of its Phase 1a clinical trial. Notably, no dose-limiting toxicities were reported during this phase, indicating a positive outcome for the trial's safety profile. Successful completion of dosing with no reported toxicities suggests significant progress in the clinical trial, potentially enhancing investor confidence and market position.

TransCode Therapeutics Inc. announced the effective date for a 1-for-28 reverse stock split, which will take effect on October 30, 2023. The reverse split aims to increase the per-share trading price of the company's common stock to meet the minimum bid price requirement for continued listing on the Nasdaq. Shareholders will receive one new share for every 28 shares they currently own, and the company will notify the Nasdaq of the split. The reverse stock split is a strategic move to maintain Nasdaq listing requirements, which may influence market perception and trading dynamics.

TransCode Therapeutics, Inc. announced a 1-for-28 reverse stock split approved by its Board of Directors and stockholders to comply with Nasdaq's minimum bid price requirements. This split will convert 28 shares of common stock into one new share, reducing the total outstanding shares from approximately 23.3 million to about 833,620. Fractional shares will not be issued, and stockholders will receive whole shares instead. The effective date of the reverse split will be announced later. Vstock Transfer LLC will serve as the exchange agent for this process. The reverse stock split is a strategic move to maintain Nasdaq listing, which could moderately influence market perception and stock performance.

TransCode Therapeutics (NASDAQ: RNAZ) is advancing its Phase 1a trial of TTX-MC138, an RNA-based therapy targeting microRNA-10b in metastatic cancer. Thirteen patients have received doses with no significant toxicities, and two of the eight remaining patients show stable disease after seven months. Early data indicate target engagement and a dose-response relationship, supporting progression to Phase 1b for further evaluation of safety and anti-tumor activity. Advancing to Phase 1b indicates significant progress in clinical development, potentially impacting future performance and investor sentiment.

TransCode Therapeutics, Inc. announced progress in its Phase 1a clinical trial of TTX-MC138 for metastatic cancer, with 13 patients treated at escalating doses and no significant safety or dose limiting toxicities reported. Two patients have maintained stable disease for at least seven months. Preliminary pharmacokinetic and pharmacodynamic analyses indicate target engagement of miR-10b, supporting further advancement to a Phase 1b trial to evaluate safety and anti-tumor activity. The trial's positive results and advancement to Phase 1b could significantly enhance TransCode's market position and investor sentiment.

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) reported progress in its Phase 1a clinical trial of TTX-MC138 for metastatic cancer, with 13 patients treated across four dose levels. Eight patients continue receiving treatment, with two showing stable disease after seven doses. No significant safety issues have been reported, and preliminary pharmacokinetic (PK) data aligns with preclinical results. The trial is set to advance to a Phase 1b dose expansion based on favorable tolerability and PK/PD results. RNAZ stock rose 4.89% to $0.43 in premarket trading. The advancement to Phase 1b and positive trial results indicate significant potential for future performance and investor sentiment.

TransCode Therapeutics Inc. (RNAZ) has received a rating upgrade to 'Buy' from analysts, reflecting increased confidence in the company's potential for growth and performance in the biotechnology sector. This upgrade is based on recent advancements in their therapeutic pipeline and positive market sentiment surrounding RNA-based treatments. Investors are encouraged to consider this upgrade as a signal of the company's improving prospects. The rating upgrade indicates significant confidence in the company's future performance and market position.

TransCode Therapeutics Inc. has initiated the initial dosing in the fourth cohort of its Phase 1 clinical trial for TTX-MC138, a treatment aimed at addressing cancer. This milestone marks a significant step in the company's development of RNA-based therapeutics, potentially enhancing its pipeline and advancing its clinical research efforts. The initiation of dosing in a Phase 1 clinical trial represents a significant advancement in the company's drug development process, which could positively influence its market position and investor sentiment.

TransCode Therapeutics, Inc. has completed a registered direct offering, selling 10,250,000 shares of common stock and warrants at $0.98 per share, generating approximately $10 million in gross proceeds. The funds will primarily support product development activities, including clinical trials for its lead candidate, TTX-MC138, and for general corporate purposes. ThinkEquity served as the sole placement agent for the offering, which was conducted under an effective shelf registration statement with the SEC. The capital raised will support key clinical trials and product development, potentially influencing the company's financial performance and market position.

TransCode Therapeutics, Inc. has announced a registered direct offering priced at-the-market under Nasdaq rules. The offering is expected to provide the company with additional capital to support its operations and development initiatives. Details regarding the number of shares and pricing have been disclosed, with the offering aimed at institutional investors. The transaction is anticipated to close shortly, subject to customary closing conditions. The registered direct offering is likely to provide necessary capital but may not significantly alter the company's overall trajectory.

The US Safety Review Committee has approved TransCode Therapeutics to open the fourth cohort in its Phase I trial of TTX-MC138 for metastatic cancers, following favorable safety data from cohort three. The fourth cohort will receive a dose nearly 50% higher than the previous one, with ongoing treatment contingent on safety and disease progression. Six out of nine subjects remain under treatment, with the longest having received seven doses over seven months. The trial includes dose-escalation and dose-expansion stages to assess tolerability, safety, and potential clinical activity. The SRC also approved enrolling more subjects in cohort three to enhance safety data. Analysis of pharmacodynamic and pharmacokinetic activity from the first two cohorts is underway, aligning with preclinical findings. TTX-MC138 targets microRNA-10b, linked to metastatic progression. Approval to advance the trial and expand enrollment is a significant step that could enhance the therapy's safety profile and clinical data.

TransCode Therapeutics (RNAZ) announced that its Safety Review Committee has approved the opening of a fourth group in its Phase 1 trial aimed at treating metastatic cancers. This development marks a significant step in the company's clinical research efforts. The approval to expand the trial indicates a significant advancement in TransCode's clinical strategy, potentially enhancing its market position.